title: Imatinib mesylate induces hypophosphatemia in patients with chronic myeloid leukemia in late chronic phase, and this effect is associated with response.
abstract: Imatinib is the drug of first choice for most patients with chronic phase chronic myeloid leukemia (CML). Although it is generally well tolerated, a number of hematological and nonhematological side-effects have been described. We report here that imatinib induces hypophosphatemia in a high proportion of our series of CML patients previously treated with interferon alpha, and that this previously unreported side effect is associated with response.
authors.affiliation: Department of Hematology, Hospital de Getafe, Madrid, Spain.
authors.forename: S
authors.initials: S
authors.lastname: Osorio
authors.forename: A García
authors.initials: AG
authors.lastname: Noblejas
authors.forename: A
authors.initials: A
authors.lastname: Durán
authors.forename: J L
authors.initials: JL
authors.lastname: Steegmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D001549:Benzamides; D002118:Calcium / Q000097:blood; D015331:Cohort Studies; D005260:Female; D006801:Humans; D017674:Hypophosphatemia / Q000139:chemically induced*; D000068877:Imatinib Mesylate; D016898:Interferon-alpha / Q000627:therapeutic use; D007684:Kidney Tubules / Q000187:drug effects* / Q000378:metabolism; D015466:Leukemia, Myeloid, Chronic-Phase / Q000097:blood / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010281:Parathyroid Hormone / Q000097:blood; D010710:Phosphates / Q000378:metabolism; D010879:Piperazines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011743:Pyrimidines / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D012189:Retrospective Studies; D016896:Treatment Outcome
chemical_list: D001549:Benzamides; D016898:Interferon-alpha; D010281:Parathyroid Hormone; D010710:Phosphates; D010879:Piperazines; D011743:Pyrimidines; D000068877:Imatinib Mesylate; D002118:Calcium